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Encephalopathy or hepatic encephalopathy?
These are clinical criteria and they are described, although not
in their exact, original form [5], in columns 2 and 3 of the table.
However, the table also depicts stages, characterized by paral-
lel alterations in consciousness, cognitive/behavioural features,
neurological ﬁndings, and electroencephalographic changes. Such
correspondence has never been established, which is the reason
why Conn and co-workers proposed the use of an index, not
unlike the Child–Pugh score, combining the independent scores
of ﬁve dimensions (mental state based on theWest Haven criteria,
Trail Making Test A, asterixis, electroencephalographic slowing
and arterial ammonia levels) [5]. In addition, the classiﬁcation of
electroencephalographic changes reported in column 5 of the
table does not correspond to either the one proposed by Conn
et al. [5] or to more modern ones [6], most likely in relation to a
typo or an alignment problem. An errata corrige on the involun-
tarily misleading information provided in Table 2 of the paper
might be necessary.
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Letters to the EditorTo the Editor:
We read with interest the paper by Ginès and co-authors on the
management of critically-ill cirrhotic patients [1]. However, we
have some concerns on the section on management of hepatic
encephalopathy. The authors seem to base their recommenda-
tions on a ‘statistical’ rather than a pathophysiological deﬁnition
of the syndrome, grouping under the heading ‘severe hepatic
encephalopathy’ a set of different neuropsychiatric symptoms
arising in critically-ill cirrhotic patients, to include mental abnor-
malities relating to sepsis, electrolyte imbalance, and even the
side- or desired-effects of drugs such as opioids and benzodiaze-
pines. Within this frame, they state that ammonia levels should
not be measured, as they provide no clinical information nor do
they relate to clinical outcomes. While we agree with the authors
that patients with cirrhosis, especially if critically-ill, may present
with more than one metabolic encephalopathy, and these may all
contribute and worsen the clinical picture, it seems to us that an
effort should be made to differentiate hepatic encephalopathy
from other forms of metabolic/toxic neuropsychiatric distur-
bance. For example, we need to be reasonably sure that the
encephalopathy we refer to in order to deﬁne fulminant hepatic
failure is hepatic encephalopathy, as we would not want to list
for transplant a patient with hepatitis who is confused because
of hypoglycaemia, or opioid/benzodiazepine overdose. In this
respect, ammonia levels seem useful, as they reﬂect hepatic fail-
ure and portal-systemic shunting [2], they correlate with recogni-
sed, quantiﬁed indices of hepatic encephalopathy, and they
predict the development of hepatic encephalopathy over time
[3]. Notably, sepsis, electrolyte imbalance, and psychoactive drugs
cause neuropsychiatric abnormalities in critically-ill patients with
no liver dysfunction [4]: we would not diagnose these patients
with hepatic encephalopathy, we would not expect them to be
hyperammonaemic and we would not treat them with ammo-
nia-lowering drugs such as non-absorbable disaccharides/antibi-
otics. Critically-ill cirrhotic patients are no exception. Should
they present with more than one potential cause for neuropsychi-
atric dysfunction, each cause should be identiﬁed and treated
according to its pathophysiology. Finally, there seems to be some
confusion in Table 2, in relation to the West Haven criteria [5].928 Journal of Hepatology 2012 vol. 57 j 921–934
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Reply to: ‘‘Encephalopathy or hepatic encephalopathy?’’
Management of critically-ill cirrhotic patients patients with acute liver failure as well as critically-ill cirrhotic
patients.
Finally, Montagnese et al. raise concerns about the variables to
be included in the West-Haven criteria [1]. Indeed, the criteria
presented in Table 3 [4] do not correspond to the ‘‘original’’ West
Haven criteria [6]. Unfortunately, numerous studies have
employed variations of these criteria [7]. In this review, we have
selected one of these criteria including level of consciousness,
intellectual behavior, neurological ﬁndings, and electroencepha-
lographic (EEG) abnormalities [8] in an attempt to be exhaustive.
Montagnese et al. are right in that there may not be a parallel
between consciousness, behavior, other neurological ﬁndings,
and EEG changes, which represents a limitation of these criteria.
An index score comparable to the Child–Pugh score, combining
the independent scores of these variables could be more accurate
[6]. However, no consensus exists yet on an optimal scoring
system.
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JOURNAL OF HEPATOLOGYTo the Editor:
In response to Montagnese et al. [1], we fully agree that hepatic
encephalopathy is a multifactorial syndrome which may result
from impaired liver function, portosystemic shunts as well as
from non-hepatic factors including sepsis, electrolyte imbalance,
and sedative agents. None of the manifestations of hepatic
encephalopathy are speciﬁc to any of the mechanisms involved.
Although we do not clearly understand what a ‘‘statistical deﬁni-
tion’’ means in this context, we also agree that, as it is multifac-
torial and non-speciﬁc, ‘‘hepatic encephalopathy’’ might be better
termed as ‘‘encephalopathy’’ in critically-ill cirrhotic patients
who frequently have several precipitating factors. Elevated blood
ammonia levels are the hallmark of encephalopathy in cirrhosis.
However, the correlation between blood ammonia and severity of
encephalopathy is weak [2]. In addition, due to a marked impair-
ment in liver function, any critically-ill cirrhotic patient is
expected to have elevated blood ammonia levels, whatever the
severity of encephalopathy. Practically, the ﬁndings of elevated
blood ammonia levels in this population may not exclude the
contribution of non-hepatic factors in the occurrence of neuro-
psychiatric changes. This is the reason why, in line with others
[3], we have suggested that the systematic determination of
blood ammonia levels is unlikely to be useful in the management
of critically-ill cirrhotic patients [4].
As pointed out by Montagnese et al. [1], whether or not non-
hepatic factors are involved in the occurrence of encephalopathy,
in patients with acute liver failure, is a crucial issue. Indeed, while
the prognostic value of ‘‘spontaneous’’ encephalopathy (i.e.
encephalopathy only related to impaired liver function) is
unequivocally poor in acute liver diseases, it would be highly
questionable to consider transplantation if encephalopathy is
only related to non-hepatic factors. However, the issue of patients
with acute liver failure is clearly different from that of critically-
ill cirrhotic patients. In addition, any patient with acute liver fail-
ure is expected to have high blood ammonia levels, whatever
non-hepatic factors are involved in the mechanisms of encepha-
lopathy [5]. No threshold value of blood ammonia would allow a
clear differentiation between ‘‘hepatic encephalopathy’’ and
‘‘non-hepatic encephalopathy’’. Careful analysis of the potential
contributing factors is still essential in the management ofJournal of Hepatology 2012 vol. 57 j 921–934 929
